Resolutsiooni liik: Riigikantselei resolutsioon
Viide: Phoenix Pharmahandel GmbH &Co KG / 01.10.2019 / ; Riigikantselei / 09.10.2019 / 7-15
/19-01399
Resolutsiooni teema: Pöördumise edastamine
Adressaat: Sotsiaalministeerium
Ülesanne: Edastame peaministrile saadetud kirja.
Tähtaeg:
Kontroll: Johannes Merilai
Kinnitaja: Maimu Mesi, Peaministri büroo referent
Kinnitamise kuupäev: 03.01.2020
Resolutsiooni koostaja: Maimu Mesi
[email protected], 693 5703
‘wuziuu sxIgi1cantseeisse
7” a
09. 10, 2919
PHOENIX
SE- Pfinqsw€,d,ra6. 0-i 2 - 55199 Varnhein Stefan Herfeld
Executive Board Member
Mr. JUn Ratas
Prime Minister of Estonia PHOENIX Pharma SE
Stenbock House
Rahukohtu 3 PfingstweidstraRe 10-12
- 68199 Mannheim, Germany
10130 Tallinn Phone +49 621 8505—251
Estonia Fax +49 621 8505—200 251
s.
[email protected]
October 1, 2019
Subject: Changes in pharmacy retail market legislation entering into force on 1 April 2020
Dear Prime Minister,
With this letter the PHOENIX group would like to address the serious concern related to major changes
in Estonian law affecting whole pharmacy retail market and to protection of significant investments
of Germany headquartered PHOENIX group in the Republic of Estonia.
PHOENIX group is a leading pharmaceutical trader in Europe. In pharmaceutical wholesale PHOENIX
group is active in 26 European countries supplying pharmacies and medical institutions with
medicines and other health products. In pharmacy retail PHOENIX group operates more than 2,500
pharmacies in 14 countries most of them operate under the corporate brand RENU.
—
We entered the Estonian market after acquisition of Finnish Tamro group in 2001. During the years
of activity in Estonia we have developed pharmaceutical wholesale activity and invested into and built
up an operation of more than 80 BENU pharmacies. Today, PHOENIX group through BENU Apteek Eesti
OU is one of the major service providers to the Estonian people.
With the great concern we have observed the changes in Estonian legislation regarding
pharmaceutical sector. In 2014 and 2015 amendments were adopted to the Estonian Medicinal
Products Act stipulating that wholesalers of medicinal products are prohibited from having holdings
in general pharmacies, or having any other dominant influence over holdings that have activity licence
of a general pharmacy. In addition, a requirement was established that a pharmacist must hold more
than 50% of the shares of the pharmacy company.
PHOENIX Pharma SE Pfingstweidstral0e ‘0—12 Executive Board:
Registered Office: Mannheim 68199 Mannheim
Helmut Fischer
Local Court Mannheim 119.4 727494 Germany
Frank GrolSe-Natrop
VAT Req No. DE 311 309 783 Address: Scefan Herfeld
68197 Mannheim
Creditor Identifier: Germany
DE7SZZZ00002OI 7868
Phone +49 621 8505—0
PHOENIX
The above—mentioned amendments have a significant impact on the activities of the PHOENIX group
in Estonia and endangers the availability of medicines in Estonia. As a consequence of the
amendments to the Medicinal Products Act, PHOENIX group must divest its holdings in the pharmacies
operating in Estonia by 1 April 2020 at the latest or wind up their activities.
However, the amendments to the Medicinal Products Act do not prescribe any compensation for
compulsory dissolution of the operation of general pharmacies belonging to wholesalers. As far as
the PHOENIX group is aware, no realistic steps have been taken to solve the specified problem by
drafting an Act covering the compensation package to investors deriving from expropriation.
Furthermore, no analysis have been made to specify how the availability of medicines is affected by
—
the law amendments and guaranteed after 1 April 2020. It should be noted that enforcement of the
law amendments may lead to closing almost 300 pharmacies in Estonia as of 1 April 2020.
The planned execution of the changes in the pharmacy sector is in the clear contradiction with the
reputation of Estonia as a modern and reliable investment environment that is well known in Europe
and in Germany, in particular.
I kindly ask and appreciate if you would find an opportunity to personally meet with me in the near
future in Estonia to discuss this topic.
Thank you very much for the consideration you will give to this request and I remain at your disposal
should you need any further information or propose time for the meeting (contact person in Estonia:
Mr. Leon Jankelevitsh, Managing Director Tamro Baltics, e—mail
[email protected], phone
+37256 220 133).
Si
of the Executive Board Retail
Page 2 of 2